HAEMONETICS CORPHAE
HAEMONETICS CORP Segments Disclosure
SEGMENT AND ENTERPRISE-WIDE INFORMATION
The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company’s reporting structure aligns with its operating structure of three global business units and the information that is regularly reviewed by the Company’s chief operating decision maker (“CODM”), identified as the Company’s Chief Executive Officer.
The Company’s reportable and operating segments are as follows:
•Plasma
•Blood Center
•Hospital
The CODM measures and evaluates the operating segments based on operating income for purposes of assessing business performance and allocating resources. Certain corporate expenses and amounts considered to be non-recurring or non-operational are excluded from segment operating income. These items include acquisition, integration and divestiture related costs, amortization of acquired assets, restructuring costs, restructuring related costs, a provision for pre-acquisition inventory and inventory purchase commitments transferred from the Attune Medical acquisition that was deemed not recoverable, digital transformation costs related to the upgrade of the Company’s enterprise resource planning system, impairments and write downs, costs related to compliance with the European Union Medical Device Regulation (“EU MDR”) and In Vitro Diagnostic Regulation (“EU IVDR”), unusual or infrequent and material litigation-related charges and gains, losses on dispositions and sale of assets, remeasurement of the contingent consideration and unusual or infrequent gains such as on repurchases of convertible notes or divestitures. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. During the fourth quarter of fiscal 2025, the CODM began reviewing financial information including allocations of certain corporate costs including global functional support and overhead costs determined to benefit the segments. The prior period segment disclosures have been recast to reflect the new presentation.
The Company does not track its assets by segment, and as a result it is not practical to show assets or depreciation by segment. Consequently, the Company’s CODM does not review assets by segment when assessing business performance and allocating resources.
Selected information by reportable segment is presented below:
| Year Ended | |||||||||||||||||
| 2026 | 2025 | 2024 | |||||||||||||||
| (Dollars in Thousands) | |||||||||||||||||
| Net revenues: | |||||||||||||||||
| Plasma | $ | 524,456 | $ | 535,431 | $ | 569,535 | |||||||||||
| Blood Center | 221,267 | 261,124 | 283,231 | ||||||||||||||
| Hospital | 588,304 | 564,269 | 456,289 | ||||||||||||||
| Total net revenues | $ | 1,334,027 | $ | 1,360,824 | $ | 1,309,055 | |||||||||||
| Significant segment expenses and operating performance: | |||||||||||||||||
| Plasma | |||||||||||||||||
| Cost of goods sold | $ | 214,135 | $ | 237,050 | $ | 264,042 | |||||||||||
| Selling, general and administrative | 105,323 | 98,418 | 109,729 | ||||||||||||||
| Research and development | 20,203 | 15,453 | 13,797 | ||||||||||||||
| Plasma operating income | $ | 184,795 | $ | 184,510 | $ | 181,967 | |||||||||||
| Blood Center | |||||||||||||||||
| Cost of goods sold | $ | 112,666 | $ | 142,512 | $ | 165,564 | |||||||||||
| Selling, general and administrative | 54,133 | 60,023 | 67,339 | ||||||||||||||
| Research and development | 4,492 | 5,770 | 7,956 | ||||||||||||||
| Blood Center operating income | $ | 49,976 | $ | 52,819 | $ | 42,372 | |||||||||||
| Hospital | |||||||||||||||||
| Cost of goods sold | $ | 203,227 | $ | 199,499 | $ | 167,172 | |||||||||||
| Selling, general and administrative | 247,251 | 241,760 | 209,680 | ||||||||||||||
| Research and development | 34,091 | 34,035 | 27,239 | ||||||||||||||
| Hospital operating income | $ | 103,735 | $ | 88,975 | $ | 52,198 | |||||||||||
| Corporate and unallocated expenses | |||||||||||||||||
| Amortization of acquired assets | $ | (49,812) | $ | (63,217) | $ | (35,378) | |||||||||||
| Acquisition, integration and divestiture related costs | (14,155) | (22,904) | (11,249) | ||||||||||||||
| Restructuring and restructuring related costs | (3,218) | (21,158) | (23,588) | ||||||||||||||
| Digital transformation costs | (21,526) | (20,273) | (15,667) | ||||||||||||||
| Remeasurement of contingent consideration | 1,879 | 23,022 | — | ||||||||||||||
| Impairment of intangible assets | (86,546) | (2,391) | (10,419) | ||||||||||||||
Other(1) | (8,394) | 2,434 | (15,353) | ||||||||||||||
| Operating income | 156,734 | 221,817 | 164,883 | ||||||||||||||
| Interest and other expense, net | (28,704) | (9,746) | (13,018) | ||||||||||||||
| Income before provision for income taxes | $ | 128,030 | $ | 212,071 | $ | 151,865 | |||||||||||
__________
(1) Comprised of write downs of certain assets, EU MDR and EU IVDR costs, Litigation-related charges, gain on repurchase of convertible notes, gain on sale of property, plant and equipment, PCS2® related charges, gain on divestiture, and a provision for pre-acquisition inventory and inventory purchase commitments transferred from the Attune Medical acquisition that was deemed not recoverable.
Net revenues by business unit are as follows:
| Year Ended | |||||||||||||||||
| 2026 | 2025 | 2024 | |||||||||||||||
| (Dollars in Thousands) | |||||||||||||||||
| Plasma | |||||||||||||||||
| Plasma net revenues | $ | 524,456 | $ | 535,431 | $ | 569,535 | |||||||||||
| Blood Center | |||||||||||||||||
| Apheresis | $ | 220,861 | $ | 213,134 | $ | 211,173 | |||||||||||
| Whole Blood | 406 | 47,990 | 72,058 | ||||||||||||||
| Blood Center net revenues | $ | 221,267 | $ | 261,124 | $ | 283,231 | |||||||||||
| Hospital | |||||||||||||||||
| Interventional Technologies | $ | 234,007 | $ | 255,019 | $ | 174,285 | |||||||||||
| Blood Management Technologies | 354,297 | 309,250 | 282,004 | ||||||||||||||
| Hospital net revenues | $ | 588,304 | $ | 564,269 | $ | 456,289 | |||||||||||
| Total net revenues | $ | 1,334,027 | $ | 1,360,824 | $ | 1,309,055 | |||||||||||
Depreciation and amortization, excluding impairment charges, by business unit are as follows:
| Year Ended | |||||||||||||||||
| 2026 | 2025 | 2024 | |||||||||||||||
| (Dollars in Thousands) | |||||||||||||||||
| Plasma | $ | 47,368 | $ | 48,264 | $ | 45,712 | |||||||||||
| Blood Center | 7,160 | 10,077 | 13,391 | ||||||||||||||
| Hospital | 57,189 | 57,245 | 38,112 | ||||||||||||||
| Total depreciation and amortization (excluding impairment charges) | $ | 111,717 | $ | 115,586 | $ | 97,215 | |||||||||||
Long-lived assets, comprised of property, plant and equipment, by business unit are as follows:
| March 28, 2026 | March 29, 2025 | ||||||||||
| (Dollars in Thousands) | |||||||||||
| Plasma | $ | 206,365 | $ | 189,833 | |||||||
| Blood Center | 39,677 | 40,337 | |||||||||
| Hospital | 59,719 | 53,882 | |||||||||
| Total long-lived assets | $ | 305,761 | $ | 284,052 | |||||||
Long-lived assets, comprised of property, plant and equipment, by operating regions are as follows:
| March 28, 2026 | March 29, 2025 | ||||||||||
| (Dollars in Thousands) | |||||||||||
| United States | $ | 224,699 | $ | 217,212 | |||||||
| Japan | 916 | 1,250 | |||||||||
| Europe | 32,080 | 20,024 | |||||||||
| Rest of Asia | 30,833 | 28,705 | |||||||||
| Other | 17,233 | 16,861 | |||||||||
| Total long-lived assets | $ | 305,761 | $ | 284,052 | |||||||
Net revenues by operating regions are as follows:
| Year Ended | |||||||||||||||||
| 2026 | 2025 | 2024 | |||||||||||||||
| (Dollars in Thousands) | |||||||||||||||||
| United States | $ | 982,176 | $ | 1,010,918 | $ | 970,007 | |||||||||||
| Japan | 68,200 | 62,408 | 58,087 | ||||||||||||||
| Europe | 185,019 | 175,655 | 160,142 | ||||||||||||||
| Rest of Asia | 87,212 | 92,305 | 107,536 | ||||||||||||||
| Other | 11,420 | 19,538 | 13,283 | ||||||||||||||
| Total net revenues | $ | 1,334,027 | $ | 1,360,824 | $ | 1,309,055 | |||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2026 | May 20, 2026 | Showing above |
| 2025 | May 21, 2025 | |
| 2024 | May 20, 2024 | |
| 2023 | May 22, 2023 | |
| 2022 | May 25, 2022 | |
| 2021 | May 26, 2021 | |
| 2020 | May 20, 2020 | |
| 2019 | May 22, 2019 | |
| 2018 | May 23, 2018 | |
| 2017 | May 24, 2017 | |
| 2016 | Jun 1, 2016 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.